Adiponectin in chronic hepatitis C

详细信息    查看全文

• 作者：Toru Arano (1)
  Hayato Nakagawa (2)
  Hitoshi Ikeda (3)
  Kazuhiko Koike (2)
  
• 关键词：Adiponectin ; Chronic hepatitis C ; Hepatocellular carcinoma
• 刊名：Clinical Journal of Gastroenterology
• 出版年：2013
• 出版时间：August 2013
• 年：2013
• 卷：6
• 期：4
• 页码：259-263
• 全文大小：143KB
• 参考文献：1. Kahn CR. Triglycerides and toggling the tummy. Nat Genet. 2000;25(1):6鈥?. CrossRef
  2. Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. Cell. 2001;104(4):531鈥?3. CrossRef
  3. Chawla A, Saez E, Evans RM. Don鈥檛 know much bile-ology. Cell. 2000;103(1):1鈥?. CrossRef
  4. Lowell BB. PPARgamma: an essential regulator of adipogenesis and modulator of fat cell function. Cell. 1999;99(3):239鈥?2. CrossRef
  5. Obici S, Feng Z, Arduini A, Conti R, Rossetti L. Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production. Nat Med. 2003;9(6):756鈥?1. CrossRef
  6. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259(5091):87鈥?1. CrossRef
  7. Lazar MA. The humoral side of insulin resistance. Nat Med. 2006;12(1):43鈥?. CrossRef
  8. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409(6818):307鈥?2. CrossRef
  9. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005;436(7049):356鈥?2. CrossRef
  10. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372(6505):425鈥?2. CrossRef
  11. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89(6):2548鈥?6. CrossRef
  12. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26(3):439鈥?1. CrossRef
  13. Kamada Y, Takehara T, Hayashi N. Adipocytokines and liver disease. J Gastroenterol. 2008;43(11):811鈥?2. CrossRef
  14. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology. 2009;50(3):957鈥?9. CrossRef
  15. Ohki T, Tateishi R, Sato T, Masuzaki R, Imamura J, Goto T, et al. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin Gastroenterol Hepatol. 2008;6(4):459鈥?4. CrossRef
  16. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116(7):1784鈥?2. CrossRef
  17. Chen MP, Tsai JC, Chung FM, Yang SS, Hsing LL, Shin SJ, et al. Hypoadiponectinemia is associated with ischemic cerebrovascular disease. Arterioscler Thromb Vasc Biol. 2005;25(4):821鈥?. CrossRef
  18. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003;23(1):85鈥?. CrossRef
  19. Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab. 2002;87(6):2764鈥?. CrossRef
  20. Asano T, Watanabe K, Kubota N, Gunji T, Omata M, Kadowaki T, et al. Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis. J Gastroenterol Hepatol. 2009;24(10):1669鈥?6. CrossRef
  21. Kamada Y, Matsumoto H, Tamura S, Fukushima J, Kiso S, Fukui K, et al. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J Hepatol. 2007;47(4):556鈥?4. CrossRef
  22. Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshida Y, et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology. 2003;125(6):1796鈥?07. CrossRef
  23. Koike K, Moriya K. Metabolic aspects of hepatitis C viral infection: steatohepatitis resembling but distinct from NASH. J Gastroenterol. 2005;40(4):329鈥?6. CrossRef
  24. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology. 2004;126(3):840鈥?. CrossRef
  25. Arano T, Nakagawa H, Tateishi R, Ikeda H, Uchino K, Enooku K, et al. Serum level of adiponectin and the risk of liver cancer development in chronic hepatitis C patients. Int J Cancer. 2011;129(9):2226鈥?5. CrossRef
  26. Corbetta S, Redaelli A, Pozzi M, Bovo G, Ratti L, Redaelli E, et al. Fibrosis is associated with adiponectin resistance in chronic hepatitis C virus infection. Eur J Clin Invest. 2011;41(8):898鈥?05. CrossRef
  27. Korah TE, El-Sayed S, Elshafie MK, Hammoda GE, Safan MA. Significance of serum leptin and adiponectin levels in Egyptian patients with chronic hepatitis C virus associated hepatic steatosis and fibrosis. World J Hepatol. 2013;5(2):74鈥?1. CrossRef
  28. Hung CH, Lee CM, Chen CH, Hu TH, Jiang SR, Wang JH, et al. Association of inflammatory and anti-inflammatory cytokines with insulin resistance in chronic hepatitis C. Liver Int. 2009;29(7):1086鈥?3. CrossRef
  29. Chen L, Liu W, Lai S, Li Y, Wang X, Zhang H. Insulin resistance, serum visfatin, and adiponectin levels are associated with metabolic disorders in chronic hepatitis C virus-infected patients. Eur J Gastroenterol Hepatol. 2013;25(8):935鈥?1. CrossRef
  30. Liu CJ, Chen PJ, Jeng YM, Huang WL, Yang WS, Lai MY, et al. Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. J Hepatol. 2005;43(2):235鈥?2. CrossRef
  31. Khattab MA, Eslam M, Shatat M, Abd-Aalhalim H, Mousa YI, Samir F, et al. Changes in adipocytokines and insulin sensitivity during and after antiviral therapy for hepatitis C genotype 4. J Gastrointestin Liver Dis. 2012;21(1):59鈥?5.
  32. Derbala M, Rizk N, Al-Kaabi S, Amer A, Shebl F, Al Marri A, et al. Adiponectin changes in HCV-Genotype 4: relation to liver histology and response to treatment. J Viral Hepat. 2009;16(10):689鈥?6. CrossRef
  33. Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology. 2008;134(2):416鈥?3. CrossRef
  34. Cua IH, Hui JM, Bandara P, Kench JG, Farrell GC, McCaughan GW, et al. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology. 2007;46(1):66鈥?3. CrossRef
  35. Jonsson JR, Moschen AR, Hickman IJ, Richardson MM, Kaser S, Clouston AD, et al. Adiponectin and its receptors in patients with chronic hepatitis C. J Hepatol. 2005;43(6):929鈥?6. CrossRef
  36. Khattab MA, Eslam M, Aly MM, Shatat M, Hussen A, Moussa YI, et al. Association of serum adipocytokines with insulin resistance and liver injury in patients with chronic hepatitis C genotype 4. J Clin Gastroenterol. 2012;46(10):871鈥?. CrossRef
  37. Aksu HS, Kurtaran B, Onlen Y, Namiduru M, Inkaya AC, Kandemir O, et al. Association of insulin resistance, viral load, and adipokine levels with liver histology in patients with chronic hepatitis C: an observational, multicenter study in Turkey. Eur J Gastroenterol Hepatol. 2012;24(12):1393鈥?. CrossRef
  38. Petit JM, Minello A, Jooste V, Bour JB, Galland F, Duvillard L, et al. Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients. J Clin Endocrinol Metab. 2005;90(4):2240鈥?. CrossRef
  39. Zografos TA, Liaskos C, Rigopoulou EI, Togousidis E, Makaritsis K, Germenis A, et al. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C. Am J Gastroenterol. 2008;103(3):605鈥?4. CrossRef
  40. Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology. 2008;135(1):111鈥?1. CrossRef
  41. Chu SH, Lee MK, Ahn KY, Im JA, Park MS, Lee DC, et al. Chemerin and adiponectin contribute reciprocally to metabolic syndrome. PLoS ONE. 2012;7(4):e34710. CrossRef
  42. Man K, Ng KT, Xu A, Cheng Q, Lo CM, Xiao JW, et al. Suppression of liver tumor growth and metastasis by adiponectin in nude mice through inhibition of tumor angiogenesis and downregulation of Rho kinase/IFN-inducible protein 10/matrix metalloproteinase 9 signaling. Clin Cancer Res. 2010;16(3):967鈥?7. CrossRef
  43. Saxena NK, Fu PP, Nagalingam A, Wang J, Handy J, Cohen C, et al. Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. Gastroenterology. 2010;139(5):1762-73, 73 e1鈥揺5.
  44. Nkontchou G, Bastard JP, Ziol M, Aout M, Cosson E, Ganne-Carrie N, et al. Insulin resistance, serum leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis. J Hepatol. 2010;53(5):827鈥?3. CrossRef
  45. Hung CH, Wang JH, Hu TH, Chen CH, Chang KC, Yen YH, et al. Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. World J Gastroenterol. 2010;16(18):2265鈥?1. CrossRef
  46. Khattab MA, Eslam M, Mousa YI, Ela-adawy N, Fathy S, Shatat M, et al. Association between metabolic abnormalities and hepatitis C-related hepatocellular carcinoma. Ann Hepatol. 2012;11(4):487鈥?4.
  47. Chen MJ, Yeh YT, Lee KT, Tsai CJ, Lee HH, Wang SN. The promoting effect of adiponectin in hepatocellular carcinoma. J Surg Oncol. 2012;106(2):181鈥?. CrossRef
  48. Yamauchi T, Kadowaki T. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int J Obes (Lond). 2008;32(Suppl 7):S13鈥?. CrossRef
  49. Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, Ebinuma H, et al. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care. 2006;29(6):1357鈥?2. CrossRef
  50. von Eynatten M, Humpert PM, Bluemm A, Lepper PM, Hamann A, Allolio B, et al. High-molecular weight adiponectin is independently associated with the extent of coronary artery disease in men. Atherosclerosis. 2008;199(1):123鈥?. CrossRef
  51. Sumie S, Kawaguchi T, Kuromatsu R, Takata A, Nakano M, Satani M, et al. Total and high molecular weight adiponectin and hepatocellular carcinoma with HCV infection. PLoS ONE. 2011;6(11):e26840. CrossRef
  
• 作者单位：Toru Arano (1)
  Hayato Nakagawa (2)
  Hitoshi Ikeda (3)
  Kazuhiko Koike (2)
  
  1. Department of Gastroenterology, Toshiba General Hospital, 6-3-22 Higashi-ooi, Shinagawa-ku, Tokyo, 140-8522, Japan
  2. Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
  3. Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
  

文摘

White adipose tissue has been increasingly recognized as an important endocrine organ that secretes a number of biologically active adipokines. Adiponectin, one of the major adipokines, possesses anti-inflammatory and insulin-sensitizing properties, and its serum levels typically decline with increasing body weight. Hypoadiponectinemia has been implicated in the development of obesity-related morbidities such as dyslipidemia and cerebrovascular disease. In addition, hypoadiponectinemia has been reported to enhance hepatic steatosis, inflammation, fibrosis, and hepatocarcinogenesis in animal models or clinical liver diseases. Chronic hepatitis C (CHC) has some features which allow it to be recognized not only as a viral disease but also as a metabolic liver disease that encompasses insulin resistance, inflammation, steatosis and fibrosis. CHC is another disease in which adipokines may represent a link between viral infection and steatosis, or metabolic disturbance. In this report, data indicating a possible role of adiponectin in CHC are summarized.